Showing 1311-1320 of 3024 results for "".
- Risk-Benefit Profile of Ozanimod for Multiple Sclerosis Did Not Change With COVID-19https://practicalneurology.com/news/risk-benefit-profile-of-ozanimod-for-multiple-sclerosis-did-not-change-with-covid-19/2469834/In the open-label extension DAYBREAK study (NCT02576717) among participants in 4 clinical trials of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for multiple sclerosis (MS), the effect of COVID-19 was evaluated. The 2,494 par
- Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosishttps://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c
- Nanocrystalline Gold Treatment Produces Measurable Metabolic Effects in Parkinson Disease and Multiple Sclerosishttps://practicalneurology.com/news/nanocrystalline-gold-treatment-produces-measurable-metabolic-effect-parkinson-disease-and-multiple-sclerosis/2469661/Across 2 phase 2 clinical trials, for Parkinson disease (PD; NCT03815916) and multiple sclerosis (MS; NCT03993171), treatment with nanocrystalline gold (CNM-Au8; Clene Nanom
- Evobrutinib Reduces Relapse Rate, Lesion Load, and Neurofilament Light Levelshttps://practicalneurology.com/news/evobrutinib-reduces-relapse-rate-lesion-load-and-neurofilament-light-levels/2469571/Post-hoc analysis of data from a trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MA) for relapsing forms of multiple sclerosis (MS) showed reduced levels of neurofilament light (NfL), a biomarker of axon degeneration. Partici
- Tolebrutinib Reduces New Lesions in People with Highly Active Multiple Sclerosishttps://practicalneurology.com/news/tolebrutinib-reduces-new-lesions-in-people-with-highly-active-multliple-sclerosis/2469556/A subgroup analysis of participants with highly active multiple sclerosis (MS) in a clinical trial (NCT03889639) of tolebrutinib (Sanofi; Bridgewater, NJ) had reduced disease activity with tolebrutinib vs placebo. After 12 weeks of tre
- Nabiximols for Multiple Sclerosis-Associated Spasticity Phase 3 Studies in US Beginhttps://practicalneurology.com/news/nabiximols-for-multiple-sclerosis-associated-spasticity-phase-3-studies-in-us-begin/2469416/The first phase 3 clinical trial (NCT04203498) studying the cannabis-derived medicine nabiximols (Sativex; GW Pharmaceuticals, Carlsbad, CA) for spasticity in multiple sclerosis (MS) has been initi
- Blood Test May Help Predict Disease Progression in Individuals with Multiple Sclerosishttps://practicalneurology.com/news/blood-test-may-help-predict-disease-progression-in-individuals-with-multiple-sclerosis/2469268/A study published in Neurology shows that a blood test may help predict worsening of multiple sclerosis (MS) likely to occur within the next year. The test can detect a neurofilament light (NfL) cha
- New Drug Application for Ponesimod Was Submitted to FDAhttps://practicalneurology.com/news/new-drug-application-for-ponesimod-was-submitted-to-fda/2469195/A new drug application (NDA) for ponesimod (Janssen Pharmaceutical, Titusville, NJ) for the treatment of adults with relapsing multiple sclerosis (MS), was submitted to the Food and Drug Administration (FDA). At week 108, a statistically significant reduction in annualized relapse rate
- Ponesimod Superior to Teriflunomide for Relapsing Multiple Sclerosis in Phase 3 Trialhttps://practicalneurology.com/news/ponesimod-superior-to-teriflunomide-for-relapsing-multiple-sclerosis-in-phase-3-trial/2469015/In the phase 3 OPTIMUM study (NCT02425644), adults with relapsing multiple sclerosis (MS) treated with ponesimod (Janssen Pharmaceuticals, Titusville, NJ) had a 30.5% reduction in annualized relapse rate (ARR) compared with those treat
- Determining Optimal Treatment Strategies for Multiple Sclerosishttps://practicalneurology.com/news/determining-optimal-treatment-strategies-for-multiple-sclerosis/2468988/A review published in Lancet Neurology makes the case that well-powered randomized clinical trials to compare treatment strategies for multiple sclerosis (MS) are necessary and possible. Authore